Clinical stage drug development company Corbus Pharmaceuticals (NASDAQ: CRBP) share price has plummeted after the it announced the test results form its 52-week Phase 3 RESOLVE-1 study.
In a blow to the study, the company said that the topline results showed no significant differences in “the primary and secondary endpoints when comparing lenabasum to placebo.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, said, “We are surprised and deeply disappointed that the RESOLVE-1 trial did not meet its primary endpoint.”
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Corbus share price…
Source: TradingView
The news has seen the company’s share price sink 74.59% to $2.35 from $9.25 per share, the lowest it has been since 2016.
Robert Spiera, M.D., Co-Principal Investigator on RESOLVE-1 said “I am genuinely surprised by these results. Immunosuppressive drugs, alone or in combination, are increasingly becoming a mainstay of treatment for patients with early diffuse cutaneous SSc.
“However, the impact of these drugs on disease has not previously been studied systematically and clearly was underappreciated by the community of SSc experts.”
